N-Methoxy-N-methyl-2-methylbutanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Methoxy-N-methyl-2-methylbutanamide
• 英文别名: N-methoxy-N,2-dimethylbutanamide
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: KAKOWMZZDIZSTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Methoxy-N-methyl-2-methylbutanamide 在 4,4'-二叔丁基苯并 、 lithium 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以88%的产率得到2-甲基丁烷酰胺
  参考文献：
  名称：

  Yus, Miguel; Radivoy, Gabriel; Alonso, Francisco, Synthesis, 2001, # 6, p. 914 - 918

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基丁醇 在 N,N'-羰基二咪唑 作用下， 生成 N-Methoxy-N-methyl-2-methylbutanamide
  参考文献：
  名称：

  可见光促进未活化的CH键的选择性胺化反应，该反应通过铜-氮化物中间体用于2H-Azirine的合成。

  摘要：

  在室温下开发了一种用铜离子捕获亚胺基的新策略，所得的高价Cu（III）亚胺中间体迅速复位，形成亚硝基，然后提供2H-叠氮基。带有双铜/光氧化还原催化剂的该方案能够在较宽的范围内在温和条件下选择性活化未活化的CH键。此外，该方法还揭示了由环丁基肟衍生物产生α-酰基氨基环戊烷酮的新的扩环重排。

  DOI：

  10.1021/acs.orglett.9b03103

文献信息

• INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Tatani Kazuya

  公开号：US20120129890A1

  公开（公告）日：2012-05-24

  A compound (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物（I）[其中A代表苯环或类似结构；Y1代表C1-6烷基亚基；Y2代表单键或类似结构；R1代表氢原子、C1-6烷基团或类似结构；R2代表可能含有取代基的苯基、可能含有取代基的5元芳香杂环、可能含有取代基的6元芳香杂环或类似结构；R3代表卤素原子、C1-6烷氧基团或类似结构；R4代表氢原子或类似结构；R5代表氢原子或类似结构]或其药物可接受的盐。此外，本发明的化合物（I）可用作治疗或预防LUTS的药物，特别是OAB的各种症状。
• PYRROLOPYRIMIDINE ITK INHIBITORS
  申请人：ACLARIS THERAPEUTICS, INC.

  公开号：US20200048262A1

  公开（公告）日：2020-02-13

  Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

  本文披露了一种芳基吡啶酮化合物和组合物，适用于治疗由ITK介导的疾病，如炎症，其结构如下式（I）-（IV）： 其中R基团，m，n和X的定义如详细描述中所述。还提供了在人类或动物主体中抑制ITK活性的方法。
• Aralkyl amines as cannabinoid receptor modulators
  申请人：Shah K. Shrenik

  公开号：US20070088058A1

  公开（公告）日：2007-04-19

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和格林-巴利综合症）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍，包括酒精和尼古丁成瘾，治疗肥胖症或进食障碍，以及治疗哮喘、便秘、慢性肠假性梗阻和肝硬化。
• Peptidic Constructs with Amino Acid Surrogates
  申请人：SHARMA SHUBH D.

  公开号：US20110263818A1

  公开（公告）日：2011-10-27

  Peptidic constructs including at least one ring-constrained amino acid surrogate of formula I: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , and y are as defined in the specification, and a plurality of amino acid residues.

  含有至少一个环限制性氨基酸替代物I的肽构建物，其中R1、R2、R3、R4、R5、R6a、R6b、R7和y如规范中定义，以及多个氨基酸残基。
• Indole derivative or pharmaceutically acceptable salt thereof
  申请人：Tatani Kazuya

  公开号：US08680120B2

  公开（公告）日：2014-03-25

  A compound (I) of the present invention, which has an EP1 receptor antagonism: [wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物(I)：[其中，A代表苯环或类似物；Y1代表C1-6烷基；Y2代表单键或类似物；R1代表氢原子，C1-6烷基或类似物；R2代表苯基，可以有取代基，也可以是5-成员芳香族杂环环，可以有取代基，也可以是6-成员芳香族杂环环，可以有取代基或类似物；R3代表卤素原子，C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可以用作治疗或预防下尿路症状，特别是膀胱过度活动症的各种症状的药物。